Research Highlight |
Featured
-
-
-
News & Views |
Treating advanced kidney cancer—miles to go before we sleep
A randomized phase III trial comparing pazopanib with sunitinib in patients with advanced clear cell renal cell carcinoma showed that although progression-free survival and overall survival were similar, pazopanib was better tolerated. Recent advances in genomics and metabolomics have provided novel insights that could be leveraged to improve therapy.
- W. Marston Linehan
- & Ramaprasad Srinivasan
-
-
Review Article |
Treatment selection in metastatic renal cell carcinoma: expert consensus
The advances in the field of targeted therapy for the treatment of renal cell carcinoma have improved outcomes for patients dramatically. In this Review article, an expert consensus opinion for the optimal use of these targeted anticancer therapies for the treatment of patients with renal cell carcinoma is outlined.
- Bernard Escudier
- , Cezary Szczylik
- & Martin Gore
Browse broader subjects
Browse narrower subjects
- Acid, base, fluid, electrolyte disorders
- Acute kidney injury
- Chronic kidney disease
- Fanconi syndrome
- Glomerular diseases
- Interstitial disease
- Lupus nephritis
- Nephritis
- Nephrosclerosis
- Obstructive nephropathy
- Paediatric kidney disease
- Phosphorus metabolism disorders
- Polycystic kidney disease
- Renal artery stenosis
- Renal calculi
- Renal cancer
- Renal fibrosis
- Thrombotic microangiopathies
- Toxin-induced nephropathy
- Urinary tract infection